Shares of SkinBioTherapeutics plc (LON:SBTX – Get Free Report) dropped 6.5% during mid-day trading on Monday . The company traded as low as GBX 10.61 and last traded at GBX 10.75. Approximately 392,247 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 2,906,237 shares. The stock had previously closed at GBX 11.50.
SkinBioTherapeutics Stock Down 5.7%
The firm has a market capitalization of £26.88 million, a PE ratio of -64.83 and a beta of 0.11. The company has a debt-to-equity ratio of 11.77, a current ratio of 6.14 and a quick ratio of 10.01. The company has a 50-day moving average price of GBX 10.50 and a 200 day moving average price of GBX 10.95.
SkinBioTherapeutics (LON:SBTX – Get Free Report) last released its earnings results on Monday, June 8th. The company reported GBX (0.31) earnings per share (EPS) for the quarter. SkinBioTherapeutics had a negative return on equity of 5.25% and a negative net margin of 8.73%.The business had revenue of GBX 217 million for the quarter.
About SkinBioTherapeutics
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
See Also
- Five stocks we like better than SkinBioTherapeutics
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
